Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Capital Area Research

Neither a doctor nor a teaching hospital

Research payments

$4,103,837

584 payments

Through program year 2025, Capital Area Research is reported as receiving $4,103,837 in research payments, across 584 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $696,856 15
2024 Research $708,689 22
2023 Research $644,917 177
2022 Research $1,163,725 145
2021 Research $299,519 188
2020 Research $269,425 20
2019 Research $320,706 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $3,346,847 33 payments
  2. AstraZeneca Pharmaceuticals LP $325,971 14 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $224,915 49 payments
  4. Novo Nordisk AS $84,756 450 payments
  5. Medtronic, Inc. $56,053 12 payments
  6. Medtronic Vascular, Inc. $40,311 14 payments
  7. AstraZeneca UK Limited $19,911 2 payments
  8. Pfizer Inc. $3,093 4 payments
  9. Merck Sharp & Dohme Corporation $1,980 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $1,498,693 6 payments
  2. A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $720,056 2 payments
  3. Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) $559,877 5 payments
  4. A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $208,404 7 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $175,678 6 payments
  6. A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An ""Inclisiran First"" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/DL) Despite Receiving Maximally Tolerated Statin Therapy (Victorion-Initiate) $103,837 2 payments
  7. AdaptResponse $96,364 26 payments
  8. Nn9535-4533 $84,756 450 payments
  9. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $84,541 14 payments
  10. BAY94-8862 LCM HFmr/pEF (EF 40%) $82,181 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record